CEO Dr Deborah O’Neil and the NovaBiotics team will be attending the BIO CEO & Investor Conference, hosted by the Biotechnology Innovation Organization on the 16th-18th February 2021. Meet with us through the event portal BIO CEO & Investor Event to learn more about our financing plans and strategy for our exciting pipeline of first-in-class antimicrobial and respiratory product candidates including Nylexa for Covid-19.
- Appointment of Dr Trevor Phillips to the Board of NovaBiotics
- Publication of NovaBiotics’ peer reviewed research on cysteamine’s antiviral and anti-inflammatory mechanisms
- Additional International Organization for Standardisation (ISO) accreditations for NovaBiotics
- NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases
- NovaBiotics to Present at the H.C. Wainwright BioConnect Conference